The hydrogel-based drug delivery market size, by the end of the forecast period, will reach USD 18.1 billion. The valuation of the competitive landscape by 2024 is likely to reach USD 8.4 billion. A promising CAGR of 7.9%, will create prospects for key players in the hydrogel-based drug delivery industry.
The growing investments in research and development have helped companies innovate in terms of formulations of gels and other products. Due to this, more prospects for augmentation of drug delivery becomes possible. This elevates the demand for advanced drug delivery solutions, driving the industry size.
Owing to the growing technological infrastructure, this augmentation of drug delivery formulation becomes possible. Due to this, the overall efficiency of such systems can increase. As a result, this factor drives the demand for cutting-edge technology, and therefore, the trend is responsible for shaping the industry.
| Attributes | Key Insights |
|---|---|
| Estimated Hydrogel-based Drug Delivery Market Size in 2024 | USD 8.4 billion |
| Projected Hydrogel-based Drug Delivery Industry Value in 2034 | USD 18.1 billion |
| Value-based CAGR from 2024 to 2034 | 7.9% |
The hydrogel-based drug delivery market analysis suggests that with such trends in the sector, medical professionals can increase the biocompatibility of products. Along with this, drug loading capacity, mechanical strength, and several other key factors can be enhanced, which benefits the lucrativeness of the ecosystem.
The expansion of hydrogel-based drug delivery systems is developing newer opportunities. As different therapeutic areas are identified and explored using innovation and technological developments, better prospects for leading firms can be seen. This is another important trend governing the progress of the said realm.
To cater to such growing research activities, governments have been funding handsomely. Due to such investments, drug delivery technology is upgraded. As a result, this fulfills the demand for medical professionals. The expansion of the biopharmaceutical sector is another key contributor to the hydrogel-based drug delivery market growth. Due to the progress in the sector, the application of drug delivery systems can proliferate, creating more prospects for the application of innovative systems.
In the case of patient treatment, such systems can enable an individual to raise the treatment standard. With the elevated therapeutic outcome, the frequency of the dosage can be reduced. This can comfort patients, which can drive the demand for products in the industry.
Despite several advantages, the drug delivery system faces technical challenges. The release kinetics, drug loading efficiency, and formulation stability might be questioned, affecting the reliability of systems. As a result, this factor hampers the global hydrogel-based drug delivery market size enlargement.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The first half of the previous decade (2023 to 2033) marked the progress of the industry at a CAGR of 8.8% (H1), and the subsequent half of the decade (H2) was observed to project the progress at a CAGR of 8.5%.
| Particulars | Value CAGR |
|---|---|
| H1 | 8.8% (2023 to 2033) |
| H2 | 8.5% (2023 to 2033) |
| H1 | 7.9% (2024 to 2034) |
| H2 | 7.5% (2024 to 2034) |
The forecasted period marks depreciating progress in the first half (H1), which is at a CAGR of 7.9%. The following half of the period is likely to progress at a CAGR of 7.5%.
The decreasing progress rate of the industry is encompassed along with the decrease of 90 BPS (H1) during the first half and 100 BPS for the subsequent half (H2).
Minimally Invasive Treatments Fuel the Hydrogel-based Drug Delivery Market Size
Different trends have been governing the healthcare industry. With the growing attention toward developing technology, healthcare professionals are keen on reducing patient’s discomfort during treatment.
This induces the trend driving patients’ attention toward minimally invasive therapies. To cater to the growing demand for better treatments, healthcare professionals emphasize the controlled and sustained release of drugs through mouth and other viable media.
This reduces the demand for surgeries and operations, reducing the burden on hospitals and other medical facilities. Due to this, the trend is expected to drive the hydrogel-based drug delivery market growth during the forecasted period.
With the growing disposable income levels, another crucial trend is observed to have emerged in the industry. This trend is the growing demand for personalized medicines.
Patients are seeking comfortable and tailored solutions for respective medical conditions of patients, driving the alterations in the formulation of drug delivery systems.
Prevalence of Chronic Diseases increasing adoption of Hydrogel-based Drug Delivery
With the propelling of patients suffering from different chronic diseases, the rise in demand for appropriate treatments can be observed. To cater to the long-term treatment of patients, a frequent and timely drug release must be ensured.
This can be ensured using hydrogel-based drug delivery systems, which can time the release of drugs to avail desired results to medical professionals. With the growing use of such drugs, chronic diseases can be controlled for a longer time, ensuring better life expectancy for a patient.
Apart from chronic diseases, the geriatric population across the world is seen to have increased recently. This number is expected to increase even further in the forecasted period.
Due to this constantly increasing number, the likelihood of increasing patients suffering from different diseases will likely increase. As a result, the requirement for such drug release systems is likely to spur, driving the industry.
The requirement for sustained medication in both such cases is expected to rise, thereby emphasizing the necessity of hydrogel-based drug delivery. This factor, therefore, creates a lucrative opportunity for key players in the hydrogel-based drug delivery industry.
Raw Materials Affect the Hydrogel-based Drug Delivery Market Growth
Hydrogel formulation is vastly dependent on some specific polymers. Due to this high dependency, the industry might face various supply chain issues. The lack of availability of alternatives might hamper the production of the drug delivery system, hampering the hydrogel-based drug delivery market size.
Principal Consultant
Owing to different health issues during the historical period, the hydrogel-based drug delivery market size rose from USD 5.6 billion in 2019 to USD 7.8 billion in 2023. With the progression experienced a moderate CAGR of 6.3%, the subject industry created many opportunities for key players in the hydrogel-based drug delivery industry during this period.
The main driving force for the competitive landscape during the historical period was the growing regulatory approval for drug development. Due to this spike, a significant rise in innovation could be observed. With the proliferated patent filing, new drug testing, and release, the ecosystem developed new openings in the industry, benefitting key players in the hydrogel-based drug delivery industry.
Along with the abovementioned factor, a significant spike in collaborations in the biopharmaceutical sector was observed. Such collaborative initiatives were primarily the results of government assistance, which spurred research activities further.
In the forecasted period, the rising trend of customization and personalization is expected to govern the hydrogel-based drug delivery market growth. To cater to elevated demands, healthcare professionals are emphasizing the use of smart hydrogels.
With the help of such hydrogels, better control of drug release can be obtained, controlling circumstances and time of drug release after the intake of the drug. As a result, advanced therapeutics surge the demand for such solutions, driving the competitive landscape.
With the projected advancements in the biologics sector, the scope of hydrogels can increase. Such a driver is expected to drive sales of hydrogel-based drug delivery systems in the forecasted period.
Organizations capped with a higher revenue margin are integral parts of the Tier 1 category. Such players often generate revenue of over USD 100 million. This category is the major governing sector of the competitive landscape, holding 59.6% of the industry space.
With the higher technological innovation and the larger consumer reach, the existence of such players in the industry is diverse. As a result, organizations operating in the Tier 1 category can develop products, which can cater to the demand for premiumization. Pertaining to growing trends toward customization, products manufactured by Tier 1 organizations have high standards in terms of features and specifications.
The Tier 2 category of the ecosystem is another governing category, accounting for 26.6% of the space in the sector. Mid-sized businesses, which have expertise in terms of technology and other resources are integral parts of this Tier. The international presence of such businesses is limited, unlike the Tier 1 category.
Due to the lack of expertise in aggressive expansion through the development of products, organizations in Tier 2 have reduced reach in the industry. Owing to small-scale production, the supply in the competitive landscape is limited, which constricts the presence of such firms in the marketspace.
Despite limited global reach, with alliance and other key strategies, organizations working in the category can reach globally. This helps firms consolidate positions in the sector through exports, franchising, leasing, and various other strategies.
The collective ecosystem of Tier 1 and Tier 2 organizations shape the industry in trems of the governance of supply and procurement of medical instruments. As a result, this system drives the worldwide hydrogel-based drug delivery market size.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
With the advancement of the healthcare industry in North America, key players in the hydrogel-based drug delivery industry are likely to experience elevated prospects in the region.
The growing investments of governments in the healthcare infrastructure in key countries of Europe are likely to drive the hydrogel-based drug delivery market growth in the region. The proliferating senior population in the Asia-Pacific region contributes to the advancing industry in the region.
Forecast CAGRs from 2024 to 2034
| Countries | Forecasted CAGR |
|---|---|
| The United States of America | 3.7% |
| The United Kingdom | 4.2% |
| India | 13.3% |
The progress of the competitive landscape is estimated to occur at a sluggish CAGR of 3.7% through 2034. The government of the country has been heavily investing in the development of the healthcare infrastructure. The adoption and use of advanced drug delivery have become possible due to such initiatives.
With conscious efforts and spending on research and development, innovations in the realm have been possible, which help key players in the hydrogel-based drug delivery industry augment product offerings. Accelerated regulatory approval is another measure taken by the government of the country, fueling the progress of the sector.
Owing to different key drivers, the hydrogel-based drug delivery market size in the United Kingdom is likely to advance at a CAGR of 4.2% through 2034.
The prevalence of different chronic diseases has spiked the demand for better drug delivery systems. To cater to the rising demand for advanced medicines for life-threatening diseases, the country focuses on using advanced therapeutics.
Along with the growing diseases like pulmonary diseases, cancer, cardiovascular failure, and many more, the growing senior population is another factor, which drives the demand for controlled medicine release. Such factors drive the scope of the industry in the country.
Owing to heavy investments in the development of the healthcare ecosystem, the prospects for several allied industries are expected to rise in India. With the background of biomedicines and local medicinal fields like Ayurveda, the scope of organizations to dive deep into the sector increases. As a result of this, the pharmaceutical industry has shown a remarkable advancement in India.
This advancement is projected to augment drug delivery systems, release time of drugs, and various other parameters associated with the process. Due to such factors, the hydrogel-based drug delivery market future forecast is expected to register the highest CAGR of 13.3% through the forecasted period.
Medical professionals aim to reduce the dosage frequency to improve comfort for patients. While catering to this demand different segments can play an important role. The ocular route of administration can result in enhanced efficiency of drug release, improving the treatment offered.
| Category | Formulation Type- Tablets |
|---|---|
| Industry Share in 2024 | 43.6% |
Easy ingestion and better-targeted delivery using tablets drive the demand for this formulation-type segment. Patient compliance is a key factor fostered while designing the course of medication. Tablets being the most suited media, are likely to drive the segment.
The production cost of tablets is also negligible, which proves a key benefit for leading manufcturers. This leverages mass and batch production for tablets, and hence, drives the segment.
| Category | Distribution Channel- Retail Pharmacy Chains |
|---|---|
| Industry Share in 2024 | 18.9% |
Due to the bolstered supply chains and retail stores, the accessibility of drugs and other medicines has increased. This spurs the convenience for buyers, which drives the demand for the segment.
With diversified and comprehensive services provided by retail pharmacies, the convenience for patients increases. As a result, this is another key driver for the segment. Collaboration and partnerships among retail pharmacists are augmenting product design, benefitting the industry segment.
With the emergence of new entrants in the sector, the competitive landscape is cluttered. Different methods are employed to expand the ecosystem, which includes collaborations, mergers, acquisitions, and partnerships.
Product innovation and new product launches are two key methods that yield optimum results for both, existing players as well as new entrants. The following recent developments are fueling the global hydrogel-based drug delivery market size-
Based on the material type, the industry is categorized into Hydroxyethyl Cellulose, Hydroxypropyl Cellulose, Polyacrylic Resins, Xanthan Gum, Carboxymethyl Cellulose, Hyaluronic acid, Alginate, Collagen, Hybrid, and others.
The competitive landscape is categorized into Tablets, Gels, Films, Suppositories, Solutions, and Dressings based on formulations of compounds.
Oral, Buccal, Rectal, Vaginal, Ocular, Transdermal, and Injectable are key routes of administration in the sector.
Hospitals, Specialty Clinics, Retail Pharmacy Chains, Drug Stores, and Online Sales channels are key distribution channels in the ecosystem.
North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, and The Middle East and Africa are the key contributing regions to the industry.
The Hydrogel-based Drug Delivery Market will advance at a CAGR of 7.9% through 2034.
The industry will likely reach USD 18.1 billion by 2034.
The ecosystem will reach USD 8.4 billion in 2024.
The tablets segment will hold 43.6% of the industry share in 2024.
The hydrogel-based drug delivery market in the United States will progress at a CAGR of 3.7% through 2034.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. Material 5.2. Formulation 5.3. Route of Administration 5.4. Distribution Channel 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Material 6.1. Hydroxyethyl Cellulose 6.2. Hydroxypropyl Cellulose 6.3. Polyacrylic Resins 6.4. Xanthan Gum 6.5. Carboxymethyl Cellulose 6.6. Hyaluronic Acid 6.7. Alginate 6.8. Collagen 6.9. Hybrid 6.10. Others 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Formulation 7.1. Tablets 7.2. Gels 7.3. Films 7.4. Suppositories 7.5. Solutions 7.6. Dressings 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 8.1. Oral 8.2. Buccal 8.3. Rectal 8.4. Vaginal 8.5. Ocular 8.6. Transdermal 8.7. Injectable 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 9.1. Hospitals 9.2. Specialty Clinics 9.3. Retail Pharmacy Chains 9.4. Drug Stores 9.5. Online Sales Channel 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. South Asia 10.5. East Asia 10.6. Eastern Europe 10.7. Middle East & Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Material, Formulation, Route of Administration, and Distribution Channel for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. AstraZeneca Plc. 20.2. Columbia Laboratories, Inc. 20.3. Mylan 20.4. Teva Pharmaceuticals USA, Inc. 20.5. Blairex Laboratories, Inc. 20.6. ARx, LLC. 20.7. Endo International plc 20.8. BioDelivery Sciences International, Inc. 20.9. Indivior PLC 20.10. GSK Plc 20.11. Pfizer Inc. 20.12. Aquestive Therapeutics, Inc. 20.13. ZIM LABORATORIES LIMITED 20.14. IntelGenx Corp. 20.15. NEXGEL 20.16. Bliss GVS Pharma Ltd. 20.17. Teika Pharmaceutical Co., Ltd. 20.18. Medherant Limited 20.19. Galderma 20.20. Johnson & Johnson 20.21. Bausch and Lomb 20.22. Ferring B.V. 20.23. Ocular Therapeutix, Inc 20.24. 3M Company 20.25. Coloplast A/S 20.26. AD Surgical 20.27. AdvaCare Pharma® 20.28. McKesson 20.29. KIKGEL 20.30. Scapa Healthcare
Explore Healthcare Insights
View Reports
Hydrogel-based Drug Delivery Market
